Posted on: February 15, 2012 by Staff
Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson [...]
Tags: Enterprise Partners Venture Capital, GBS Venture Partners, H&Q Healthcare/Life Sciences Investors, Johnson & Johnson Development Corporation, Lundbeckfond Ventures, Novartis Venture Funds, Pfizer Venture Investments, Venrock Associates
Posted on: January 24, 2012 by asormani
PowerVision, a private company developing an accommodating intraocular lens, had added Johnson & Johnson Development Corporation to its list of investors in a recent closing of its Series C financing. Current investors, Venrock, Advanced Technology Ventures, and Frazier Healthcare Ventures, also participated in the round. The closing brings PowerVision’s Series C financing round to a [...]
Tags: Advanced Technology Ventures, Frazier Healthcare Ventures, Johnson & Johnson Development Corporation, Venrock
Posted on: January 6, 2012 by cnolan
Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.
Tags: Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures, Sofinnova Ventures
Posted on: July 20, 2011 by cnolan
Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.
Tags: Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Johnson & Johnson Development Corporation, Mayo Clinic, MPM Capital, Three Arch Partners
Posted on: February 2, 2011 by cnolan
Cambridge, Mass.-based vaccine development company Genocea Biosciences has named Chip Clark president and chief executive officer. Clark joined the company last August as chief business officer. Genocea is backed by investors including Johnson & Johnson Development Corporation, Skyline Ventures, MP Healthcare Venture Management and Polaris Venture Partners.
Tags: Johnson & Johnson Development Corporation, MP Healthcare Venture Management, Polaris Venture Partners, Skyline Ventures